{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,8]],"date-time":"2026-10-08T07:03:31Z","timestamp":1791443011398,"version":"4.3.3"},"reference-count":58,"publisher":"Elsevier BV","issue":"1-3","license":[{"start":{"date-parts":[[2014,4,1]],"date-time":"2014-04-01T00:00:00Z","timestamp":1396310400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2014,4,1]],"date-time":"2014-04-01T00:00:00Z","timestamp":1396310400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/100017183","name":"Janssen Scientific Affairs","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100017183","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000025","name":"National Institute of Mental Health","doi-asserted-by":"publisher","award":["HHSN-271-2008-00025-C"],"award-info":[{"award-number":["HHSN-271-2008-00025-C"]}],"id":[{"id":"10.13039\/100000025","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Schizophrenia Research"],"published-print":{"date-parts":[[2014,4]]},"DOI":"10.1016\/j.schres.2014.02.015","type":"journal-article","created":{"date-parts":[[2014,3,15]],"date-time":"2014-03-15T14:15:56Z","timestamp":1394892956000},"page":"14-22","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":33,"title":["A six month randomized controlled trial of long acting injectable risperidone 50 and 100 mg in treatment resistant schizophrenia"],"prefix":"10.1016","volume":"154","author":[{"given":"H.Y.","family":"Meltzer","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J.-P.","family":"Lindenmayer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7300-8041","authenticated-orcid":false,"given":"J.","family":"Kwentus","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"D.B.","family":"Share","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"R.","family":"Johnson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"K.","family":"Jayathilake","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"8","key":"10.1016\/j.schres.2014.02.015_bb0005","doi-asserted-by":"crossref","first-page":"1305","DOI":"10.1176\/appi.ajp.158.8.1305","article-title":"A double-blind comparative study of clozapine and risperidone in the management of severe chronic schizophrenia","volume":"158","author":"Azorin","year":"2001","journal-title":"Am. J. Psychiatry"},{"key":"10.1016\/j.schres.2014.02.015_bb0010","doi-asserted-by":"crossref","first-page":"672","DOI":"10.1192\/bjp.154.5.672","article-title":"A rating scale for drug-induced akathisia","volume":"154","author":"Barnes","year":"1989","journal-title":"Br. J. Psychiatry"},{"issue":"Suppl. 2","key":"10.1016\/j.schres.2014.02.015_bb0015","doi-asserted-by":"crossref","first-page":"S27","DOI":"10.1016\/0924-977X(96)00008-9","article-title":"Neurobiology of treatment-resistant schizophrenia: new insights and new models","volume":"6","author":"Beerpoot","year":"1996","journal-title":"Eur. Neuropsychopharmacol."},{"issue":"1","key":"10.1016\/j.schres.2014.02.015_bb0020","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1016\/j.pnpbp.2003.09.033","article-title":"Olanzapine versus clozapine in treatment-resistant or treatment-intolerant schizophrenia","volume":"28","author":"Bitter","year":"2004","journal-title":"Prog. Neuropsychopharmacol. Biol. Psychiatry"},{"issue":"4","key":"10.1016\/j.schres.2014.02.015_bb9000","first-page":"499","article-title":"Risperidone versus clozapine in treatment- resistant chronic schizophrenia: a randomized double- blind study","volume":"155","author":"Bondolfi","year":"1998","journal-title":"The Risperidone Study Group. Am. J. Psychiatry"},{"issue":"5","key":"10.1016\/j.schres.2014.02.015_bb0030","doi-asserted-by":"crossref","first-page":"683","DOI":"10.1517\/14740338.2010.506712","article-title":"Long-acting atypical injectable antipsychotics in the treatment of schizophrenia: safety and tolerability review","volume":"9","author":"Canas","year":"2010","journal-title":"Expert Opin. Drug Saf."},{"issue":"1","key":"10.1016\/j.schres.2014.02.015_bb0035","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1097\/00004714-199302000-00004","article-title":"A Canadian multicenter placebo-controlled study of fixed doses of risperidone and haloperidol in the treatment of chronic schizophrenic patients","volume":"13","author":"Chouinard","year":"1993","journal-title":"J. Clin. Psychopharmacol."},{"key":"10.1016\/j.schres.2014.02.015_bb0040","series-title":"Statistical Power Analysis for the Behavioral Sciences","author":"Cohen","year":"1977"},{"issue":"4","key":"10.1016\/j.schres.2014.02.015_bb0045","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1097\/01.wnf.0000172993.89879.0f","article-title":"Risperidone, quetiapine, and fluphenazine in the treatment of patients with therapy-refractory schizophrenia","volume":"28","author":"Conley","year":"2005","journal-title":"Clin. Neuropharmacol."},{"issue":"3","key":"10.1016\/j.schres.2014.02.015_bb0050","doi-asserted-by":"crossref","first-page":"414","DOI":"10.1176\/appi.ajp.161.3.414","article-title":"Lower risk for tardive dyskinesia associated with second-generation antipsychotics: a systematic review of 1-year studies","volume":"161","author":"Correll","year":"2004","journal-title":"Am. J. Psychiatry"},{"issue":"3","key":"10.1016\/j.schres.2014.02.015_bb0055","doi-asserted-by":"crossref","first-page":"254","DOI":"10.1177\/0269881107082119","article-title":"Long-acting risperidone improves negative symptoms in stable psychotic patients","volume":"22","author":"Curtis","year":"2008","journal-title":"J. Psychopharmacol."},{"issue":"6","key":"10.1016\/j.schres.2014.02.015_bb0060","doi-asserted-by":"crossref","first-page":"478","DOI":"10.1097\/00004714-199712000-00007","article-title":"Risperidone dose and blood level variability: accumulation effects and interindividual and intraindividual variability in the nonresponder patient in the clinical practice setting","volume":"17","author":"Darby","year":"1997","journal-title":"J. Clin. Psychopharmacol."},{"issue":"1","key":"10.1016\/j.schres.2014.02.015_bb0065","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1016\/j.schres.2003.11.001","article-title":"Pharmacokinetics and tolerability of long-acting risperidone in schizophrenia","volume":"70","author":"Eerdekens","year":"2004","journal-title":"Schizophr. Res."},{"key":"10.1016\/j.schres.2014.02.015_bb0070","series-title":"History and Current Definitions of Treatment-resistant Schizophrenia Adv Biol Psychiatry","author":"Elkis","year":"2010"},{"issue":"2\u20133","key":"10.1016\/j.schres.2014.02.015_bb0075","doi-asserted-by":"crossref","first-page":"604","DOI":"10.1016\/j.schres.2013.09.018","article-title":"A pilot double-blind comparison of d-serine and high-dose olanzapine in treatment-resistant patients with schizophrenia","volume":"150","author":"Ermilov","year":"2013","journal-title":"Schizophr. Res."},{"issue":"10","key":"10.1016\/j.schres.2014.02.015_bb0080","doi-asserted-by":"crossref","first-page":"1250","DOI":"10.4088\/JCP.v64n1017","article-title":"Treatment of schizophrenia with long-acting injectable risperidone: a 12-month open-label trial of the first long-acting second-generation antipsychotic","volume":"64","author":"Fleischhacker","year":"2003","journal-title":"J. Clin. Psychiatry"},{"issue":"2","key":"10.1016\/j.schres.2014.02.015_bb0085","doi-asserted-by":"crossref","first-page":"66","DOI":"10.1055\/s-0029-1239541","article-title":"Prospective, open study of long-acting injected risperidone versus oral antipsychotics in 88 chronically psychotic patients","volume":"43","author":"Girardi","year":"2010","journal-title":"Pharmacopsychiatry"},{"issue":"12","key":"10.1016\/j.schres.2014.02.015_bb0090","doi-asserted-by":"crossref","first-page":"1616","DOI":"10.4088\/JCP.11r06927","article-title":"Mid-term and long-term efficacy and effectiveness of antipsychotic medications for schizophrenia: a data-driven, personalized clinical approach","volume":"72","author":"Glick","year":"2011","journal-title":"J. Clin. Psychiatry"},{"key":"10.1016\/j.schres.2014.02.015_bb0095","first-page":"534","article-title":"ECDEU Assessment Manual for Psychopharmacology: revised (DHEW publication number ADM 76-338)","author":"Guy","year":"1976"},{"issue":"4","key":"10.1016\/j.schres.2014.02.015_bb0100","doi-asserted-by":"crossref","first-page":"343","DOI":"10.1111\/j.1600-0447.1997.tb09642.x","article-title":"A two-phase, double-blind randomized study of three haloperidol plasma levels for acute psychosis with reassignment of initial non-responders","volume":"95","author":"Janicak","year":"1997","journal-title":"Acta Psychiatr. Scand."},{"issue":"9","key":"10.1016\/j.schres.2014.02.015_bb0105","doi-asserted-by":"crossref","first-page":"789","DOI":"10.1001\/archpsyc.1988.01800330013001","article-title":"Clozapine for the treatment-resistant schizophrenic. A double-blind comparison with chlorpromazine","volume":"45","author":"Kane","year":"1988","journal-title":"Arch. Gen. Psychiatry"},{"issue":"6","key":"10.1016\/j.schres.2014.02.015_bb0110","doi-asserted-by":"crossref","first-page":"1125","DOI":"10.1176\/appi.ajp.160.6.1125","article-title":"Long-acting injectable risperidone: efficacy and safety of the first long-acting atypical antipsychotic","volume":"160","author":"Kane","year":"2003","journal-title":"Am. J. Psychiatry"},{"issue":"2","key":"10.1016\/j.schres.2014.02.015_bb0115","doi-asserted-by":"crossref","first-page":"261","DOI":"10.1093\/schbul\/13.2.261","article-title":"The positive and negative syndrome scale (PANSS) for schizophrenia","volume":"13","author":"Kay","year":"1987","journal-title":"Schizophr. Bull."},{"issue":"1\u20133","key":"10.1016\/j.schres.2014.02.015_bb0120","doi-asserted-by":"crossref","first-page":"230","DOI":"10.1016\/j.schres.2008.02.021","article-title":"Predicting response to atypical antipsychotics based on early response in the treatment of schizophrenia","volume":"102","author":"Kinon","year":"2008","journal-title":"Schizophr. Res."},{"issue":"1","key":"10.1016\/j.schres.2014.02.015_bb0125","doi-asserted-by":"crossref","first-page":"192","DOI":"10.1093\/schbul\/sbs150","article-title":"Long-acting injectable vs oral antipsychotics for relapse prevention in schizophrenia: a meta-analysis of randomized trials","volume":"40","author":"Kishimoto","year":"2013","journal-title":"Schizophr. Bull."},{"issue":"5","key":"10.1016\/j.schres.2014.02.015_bb0130","doi-asserted-by":"crossref","first-page":"524","DOI":"10.1016\/j.biopsych.2007.04.043","article-title":"Clozapine and \u201chigh-dose\u201d olanzapine in refractory early-onset schizophrenia: a 12-week randomized and double-blind comparison","volume":"63","author":"Kumra","year":"2008","journal-title":"Biol. Psychiatry"},{"issue":"4","key":"10.1016\/j.schres.2014.02.015_bb0135","doi-asserted-by":"crossref","first-page":"307","DOI":"10.1089\/cap.2007.0089","article-title":"Clozapine versus \u201chigh-dose\u201d olanzapine in refractory early-onset schizophrenia: an open-label extension study","volume":"18","author":"Kumra","year":"2008","journal-title":"J. Child Adolesc. Psychopharmacol."},{"issue":"8","key":"10.1016\/j.schres.2014.02.015_bb0140","first-page":"855","article-title":"Clozapine and substance abuse in patients with schizophrenia","volume":"43","author":"Lee","year":"1998","journal-title":"Can. J. Psychiatry"},{"issue":"4","key":"10.1016\/j.schres.2014.02.015_bb0145","doi-asserted-by":"crossref","first-page":"429","DOI":"10.1038\/sj.mp.4002136","article-title":"How effective are second-generation antipsychotic drugs? A meta-analysis of placebo-controlled trials","volume":"14","author":"Leucht","year":"2009","journal-title":"Mol. Psychiatry"},{"issue":"12","key":"10.1016\/j.schres.2014.02.015_bb0150","doi-asserted-by":"crossref","first-page":"1744","DOI":"10.1176\/ajp.151.12.1744","article-title":"Clinical effects of clozapine in chronic schizophrenia: response to treatment and predictors of outcome","volume":"151","author":"Lieberman","year":"1994","journal-title":"Am. J. Psychiatry"},{"key":"10.1016\/j.schres.2014.02.015_bb0155","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1111\/j.1600-0447.1987.tb10566.x","article-title":"The UKU side effect rating scale. A new comprehensive rating scale for psychotropic drugs and a cross-sectional study of side effects in neuroleptic-treated patients","volume":"334","author":"Lingjaerde","year":"1987","journal-title":"Acta Psychiatr. Scand. Suppl."},{"issue":"2","key":"10.1016\/j.schres.2014.02.015_bb0160","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1081\/BIP-120015744","article-title":"Comparison of alternative strategies for analysis of longitudinal trials with dropouts","volume":"12","author":"Liu","year":"2002","journal-title":"J. Biopharm. Stat."},{"issue":"6","key":"10.1016\/j.schres.2014.02.015_bb0170","doi-asserted-by":"crossref","first-page":"825","DOI":"10.1176\/ajp.151.6.825","article-title":"Risperidone in the treatment of schizophrenia","volume":"151","author":"Marder","year":"1994","journal-title":"Am. J. Psychiatry"},{"issue":"1","key":"10.1016\/j.schres.2014.02.015_bb0165","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1093\/oxfordjournals.schbul.a006926","article-title":"The Mount Sinai conference on the pharmacotherapy of schizophrenia","volume":"28","author":"Marder","year":"2002","journal-title":"Schizophr. Bull."},{"issue":"1","key":"10.1016\/j.schres.2014.02.015_bb0175","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1016\/S0924-9338(00)00536-8","article-title":"Long-term treatment of chronic schizophrenia with risperidone: a study with plasma levels","volume":"16","author":"Mauri","year":"2001","journal-title":"Eur. Psychiatry"},{"issue":"4","key":"10.1016\/j.schres.2014.02.015_bb0180","doi-asserted-by":"crossref","first-page":"600","DOI":"10.1176\/ajp.2006.163.4.600","article-title":"Effectiveness of clozapine versus olanzapine, quetiapine, and risperidone in patients with chronic schizophrenia who did not respond to prior atypical antipsychotic treatment","volume":"163","author":"McEvoy","year":"2006","journal-title":"Am. J. Psychiatry"},{"issue":"4","key":"10.1016\/j.schres.2014.02.015_bb0185","doi-asserted-by":"crossref","first-page":"233","DOI":"10.1016\/j.euroneuro.2005.10.006","article-title":"Plasma antipsychotic concentration and receptor occupancy, with special focus on risperidone long-acting injectable","volume":"16","author":"Medori","year":"2006","journal-title":"Eur. Neuropsychopharmacol."},{"issue":"3","key":"10.1016\/j.schres.2014.02.015_bb0190","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1590\/S1516-31802010000300007","article-title":"Efficacy and safety of atypical antipsychotic drugs (quetiapine, risperidone, aripiprazole and paliperidone) compared with placebo or typical antipsychotic drugs for treating refractory schizophrenia: overview of systematic reviews","volume":"128","author":"Melnik","year":"2010","journal-title":"Sao Paulo Med. J."},{"issue":"7","key":"10.1016\/j.schres.2014.02.015_bb0195","doi-asserted-by":"crossref","first-page":"672","DOI":"10.1001\/archpsyc.1989.01810070098017","article-title":"Duration of a clozapine trial in neuroleptic-resistant schizophrenia","volume":"46","author":"Meltzer","year":"1989","journal-title":"Arch. Gen. Psychiatry"},{"issue":"1","key":"10.1016\/j.schres.2014.02.015_bb0200","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1185\/03007999709113338","article-title":"Treatment-resistant schizophrenia\u2014the role of clozapine","volume":"14","author":"Meltzer","year":"1997","journal-title":"Curr. Med. Res. Opin."},{"issue":"3","key":"10.1016\/j.schres.2014.02.015_bb0205","doi-asserted-by":"crossref","first-page":"134","DOI":"10.3371\/CSRP.6.3.5","article-title":"Clozapine: balancing safety with superior antipsychotic efficacy","volume":"6","author":"Meltzer","year":"2012","journal-title":"Clin. Schizophr. Relat. Psychoses"},{"key":"10.1016\/j.schres.2014.02.015_bb0210","doi-asserted-by":"crossref","first-page":"393","DOI":"10.1146\/annurev-med-050911-161504","article-title":"Update on typical and atypical antipsychotic drugs","volume":"64","author":"Meltzer","year":"2013","journal-title":"Annu. Rev. Med."},{"issue":"2","key":"10.1016\/j.schres.2014.02.015_bb0215","doi-asserted-by":"crossref","first-page":"274","DOI":"10.4088\/JCP.v69n0214","article-title":"A randomized, double-blind comparison of clozapine and high-dose olanzapine in treatment-resistant patients with schizophrenia","volume":"69","author":"Meltzer","year":"2008","journal-title":"J. Clin. Psychiatry"},{"issue":"2\u20133","key":"10.1016\/j.schres.2014.02.015_bb0220","doi-asserted-by":"crossref","first-page":"144","DOI":"10.1016\/j.schres.2012.07.029","article-title":"Pimavanserin, a selective serotonin (5-HT)2A-inverse agonist, enhances the efficacy and safety of risperidone, 2mg\/day, but does not enhance efficacy of haloperidol, 2mg\/day: comparison with reference dose risperidone, 6mg\/day","volume":"141","author":"Meltzer","year":"2012","journal-title":"Schizophr. Res."},{"issue":"8","key":"10.1016\/j.schres.2014.02.015_bb0225","doi-asserted-by":"crossref","first-page":"1572","DOI":"10.2174\/138920112800784880","article-title":"Serotonin receptors as targets for drugs useful to treat psychosis and cognitive impairment in schizophrenia","volume":"13","author":"Meltzer","year":"2012","journal-title":"Curr. Pharm. Biotechnol."},{"issue":"4","key":"10.1016\/j.schres.2014.02.015_bb0230","first-page":"323","article-title":"Development, reliability and acceptability of a new version of the DSM-IV Social and Occupational Functioning Assessment Scale (SOFAS) to assess routine social functioning","volume":"101","author":"Morosini","year":"2000","journal-title":"Acta Psychiatr. Scand."},{"issue":"4","key":"10.1016\/j.schres.2014.02.015_bb0235","doi-asserted-by":"crossref","first-page":"531","DOI":"10.4088\/JCP.v65n0412","article-title":"Health-related quality of life in patients with schizophrenia during treatment with long-acting, injectable risperidone","volume":"65","author":"Nasrallah","year":"2004","journal-title":"J. Clin. Psychiatry"},{"issue":"6","key":"10.1016\/j.schres.2014.02.015_bb0240","doi-asserted-by":"crossref","first-page":"712","DOI":"10.1192\/bjp.166.6.712","article-title":"Risperidone in the treatment of patients with chronic schizophrenia: a multi-national, multi-centre, double-blind, parallel-group study versus haloperidol. Risperidone Study Group","volume":"166","author":"Peuskens","year":"1995","journal-title":"Br. J. Psychiatry"},{"issue":"12","key":"10.1016\/j.schres.2014.02.015_bb0245","doi-asserted-by":"crossref","first-page":"809","DOI":"10.1056\/NEJM199709183371202","article-title":"A comparison of clozapine and haloperidol in hospitalized patients with refractory schizophrenia. Department of Veterans Affairs Cooperative Study Group on Clozapine in Refractory Schizophrenia","volume":"337","author":"Rosenheck","year":"1997","journal-title":"N. Engl. J. Med."},{"issue":"4","key":"10.1016\/j.schres.2014.02.015_bb0250","doi-asserted-by":"crossref","first-page":"709","DOI":"10.1093\/oxfordjournals.schbul.a033412","article-title":"How long to wait for a response to clozapine: a comparison of time course of response to clozapine and conventional antipsychotic medication in refractory schizophrenia","volume":"25","author":"Rosenheck","year":"1999","journal-title":"Schizophr. Bull."},{"key":"10.1016\/j.schres.2014.02.015_bb0255","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1111\/j.1600-0447.1970.tb02066.x","article-title":"A rating scale for extrapyramidal side effects","volume":"212","author":"Simpson","year":"1970","journal-title":"Acta Psychiatr. Scand. Suppl."},{"issue":"1","key":"10.1016\/j.schres.2014.02.015_bb0260","doi-asserted-by":"crossref","first-page":"30","DOI":"10.4088\/JCP.v64n0107","article-title":"Prior antipsychotic prescribing in patients currently receiving clozapine: a case note review","volume":"64","author":"Taylor","year":"2003","journal-title":"J. Clin. Psychiatry"},{"issue":"1","key":"10.1016\/j.schres.2014.02.015_bb0265","doi-asserted-by":"crossref","first-page":"52","DOI":"10.1016\/S0006-3223(00)01026-X","article-title":"Double-blind comparison of olanzapine versus clozapine in schizophrenic patients clinically eligible for treatment with clozapine","volume":"49","author":"Tollefson","year":"2001","journal-title":"Biol. Psychiatry"},{"issue":"2","key":"10.1016\/j.schres.2014.02.015_bb0270","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1176\/appi.ajp.159.2.255","article-title":"Clozapine, olanzapine, risperidone, and haloperidol in the treatment of patients with chronic schizophrenia and schizoaffective disorder","volume":"159","author":"Volavka","year":"2002","journal-title":"Am. J. Psychiatry"},{"issue":"4","key":"10.1016\/j.schres.2014.02.015_bb0275","doi-asserted-by":"crossref","first-page":"489","DOI":"10.1007\/s00213-010-1852-5","article-title":"Long-acting injectable risperidone and metabolic ratio: a possible index of clinical outcome in treatment-resistant schizophrenic patients","volume":"210","author":"Volonteri","year":"2010","journal-title":"Psychopharmacology (Berl)"},{"issue":"1","key":"10.1016\/j.schres.2014.02.015_bb0280","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1093\/oxfordjournals.schbul.a006924","article-title":"Antipsychotic prescribing practices in the Veterans Healthcare Administration\u2014New York metropolitan region","volume":"28","author":"Weissman","year":"2002","journal-title":"Schizophr. Bull."},{"issue":"9","key":"10.1016\/j.schres.2014.02.015_bb0285","doi-asserted-by":"crossref","first-page":"1374","DOI":"10.1176\/ajp.156.9.1374","article-title":"Risperidone in treatment-refractory schizophrenia","volume":"156","author":"Wirshing","year":"1999","journal-title":"Am. J. Psychiatry"},{"issue":"3","key":"10.1016\/j.schres.2014.02.015_bb0290","doi-asserted-by":"crossref","first-page":"457","DOI":"10.1017\/S146114570500516X","article-title":"A meta-analysis of neuropsychological change to clozapine, olanzapine, quetiapine, and risperidone in schizophrenia","volume":"8","author":"Woodward","year":"2005","journal-title":"Int. J. Neuropsychopharmacol."}],"container-title":["Schizophrenia Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0920996414000814?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0920996414000814?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,12]],"date-time":"2025-10-12T19:25:13Z","timestamp":1760297113000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0920996414000814"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2014,4]]},"references-count":58,"journal-issue":{"issue":"1-3","published-print":{"date-parts":[[2014,4]]}},"alternative-id":["S0920996414000814"],"URL":"https:\/\/doi.org\/10.1016\/j.schres.2014.02.015","relation":{},"ISSN":["0920-9964"],"issn-type":[{"value":"0920-9964","type":"print"}],"subject":[],"published":{"date-parts":[[2014,4]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"A six month randomized controlled trial of long acting injectable risperidone 50 and 100mg in treatment resistant schizophrenia","name":"articletitle","label":"Article Title"},{"value":"Schizophrenia Research","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.schres.2014.02.015","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2014 Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}]}}